Does oncology research need to slow down a little bit?

Abstract

Get full access to this article

View all access options for this article.

References

Forde

Chaft

Smith

et al.

Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018; 378: 1976–1986.

Armand

Engert

Younes

et al.

Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkmate 205 trial. J Clin Oncol 2018; 36: 1428–1439.

Wolchok

Hoos

O’Day

et al.

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412–7420.

Hodi

Ballinger

Lyons

et al.

Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol 2018; 36: 850–858.

Cheson

Fisher

Barrington

et al.

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059–3068.

Cheson

Ansell

Schwartz

et al.

Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016; 128: 2489–2496.

Younes

Hilden

Coiffier

et al.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 2017; 28: 1436–1447.

Dada

. Is our future our past? Response to: refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016; 128: 2489–2496. (e-letter).

Subrahmanyam

Dong

Gusenleitner

et al.

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. J Immunother Cancer 2018; 6: 18–18.